Cargando…

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy

DNA topoisomerase II (Top2) is essential for all eukaryotic cells in the regulation of DNA topology through the generation of temporary double-strand breaks. Cancer cells acquire enhanced Top2 functions to cope with the stress generated by transcription and DNA replication during rapid cell division...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matias-Barrios, Victor M., Dong, Xuesen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866718/ https://www.ncbi.nlm.nih.gov/pubmed/36678591 http://dx.doi.org/10.3390/ph16010094

Ejemplares similares

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression
por: Li, Haolong, et al.
Publicado: (2015)

Epigenetic synthetic lethality approaches in cancer therapy
por: Yang, Haoshen, et al.
Publicado: (2019)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
por: Ju, Sang-Hyeon, et al.
Publicado: (2022)

Synthetic lethality in lung cancer and translation to clinical therapies
por: Leung, Ada W. Y., et al.
Publicado: (2016)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
por: Castells-Roca, Laia, et al.
Publicado: (2021)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
por: Topatana, Win, et al.
Publicado: (2020)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015)

Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor
por: Ezoe, Sachiko
Publicado: (2012)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

Rapid Inhibitor Discovery by Exploiting Synthetic Lethality
por: Muscato, Jacob D., et al.
Publicado: (2022)

Breast Cancer Predisposition Genes and Synthetic Lethality
por: Neiger, Hannah E., et al.
Publicado: (2021)

Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
por: Le, Bac Viet, et al.
Publicado: (2022)

Cell cycle responses to Topoisomerase II inhibition: Molecular mechanisms and clinical implications
por: Soliman, Tanya N., et al.
Publicado: (2023)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
por: Yao, Kun, et al.
Publicado: (2021)

A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents
por: Okoro, Cosmas O., et al.
Publicado: (2023)

The tumor therapy landscape of synthetic lethality
por: Zhang, Biyu, et al.
Publicado: (2021)

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
por: Murata, Stephen, et al.
Publicado: (2016)

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
por: Grossman, Scott, et al.
Publicado: (2023)

Epigenetic based synthetic lethal strategies in human cancers
por: Gao, Aiai, et al.
Publicado: (2020)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
por: Yakkala, Prasanna Anjaneyulu, et al.
Publicado: (2023)

Synthetic Lethality in Lung Cancer—From the Perspective of Cancer Genomics
por: Shimomura, Iwao, et al.
Publicado: (2019)

Overview of Ferroptosis and Synthetic Lethality Strategies
por: Kinowaki, Yuko, et al.
Publicado: (2021)

Synthetic Lethality Targeting Polθ
por: Drzewiecka, Małgorzata, et al.
Publicado: (2022)

Topoisomerase IIα in Chromosome Instability and Personalized Cancer Therapy
por: Chen, Tao, et al.
Publicado: (2014)

Protease Addiction and Synthetic Lethality in Cancer
por: Freije, José M. P., et al.
Publicado: (2011)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Development of synthetic lethality in cancer: molecular and cellular classification
por: Li, Shijie, et al.
Publicado: (2020)

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016)

The Roles of DNA Topoisomerase IIβ in Transcription
por: Madabhushi, Ram
Publicado: (2018)

Targeting DNA Topoisomerase II in Antifungal Chemotherapy
por: Kondaka, Kavya, et al.
Publicado: (2022)

Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents
por: Cowell, Ian G., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3il2653pdj26fi856p3voue5jf